Sign Out
Cerezyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease.
The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anemia after exclusion of other causes, such as iron deficiency; thrombocytopenia; bone disease after exclusion of other causes such as Vitamin D deficiency; hepatomegaly or splenomegaly.
Continue with Google